In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Economics Will Drive The Evolution Of The Medical Device Industry

Executive Summary

There has been a fundamental structural shift in the US medical device industry; economics are the driving force as early-stage financing has dried up, reimbursements have been steadily reduced and hospitals and clinics are forced to operate more efficiently. Technology Commercialization Group (TCG) looks at these changes and the implications for both large and small companies.

You may also be interested in...



Mega Medtech M&A Momentum In 2015

Medtech M&A activity has been on the rise for several years along with a surge in the number of higher-valued mega-deals, those worth at least $1 billion. Yet a survey of all deals with known values indicates that median deal value has actually declined.

Value-Based Medtech Rides The Money-Go-Round Into 2016

The M&A bonanza for companies in the medtech sector continued into 2015 and there is no end in sight in 2016 as manufacturers seek to augment and fine-tune portfolios to meet the new demands of payers and providers. Longer term, there are signs of a change in the top global medtech rankings.

Medtechs Told: Change Commercial Models Or Be Left Behind

Medical device companies working on the global stage are undergoing price and innovation productivity pressures just at the time that the markets are demanding a different type of service delivery from their suppliers. Smart manufacturers are reacting positively, with new commercial models, but they remain the exception to the rule, says the Boston Consulting Group, which is soon to release the second edition of its commercial benchmarking initiative.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel